188 related articles for article (PubMed ID: 37815829)
21. Assessment of Toxic Effects Associated With Dose-Fractionated Radiotherapy Among Patients With Cancer and Comorbid Collagen Vascular Disease.
Yoon SM; Chu FI; Ruan D; Steinberg ML; Raldow A; Lee P
JAMA Netw Open; 2021 Feb; 4(2):e2034074. PubMed ID: 33599771
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials.
Tabrizi S; Trippa L; Cagney D; Aizer AA; Tanguturi S; Ventz S; Fell G; Bellon JR; Mamon H; Nguyen PL; D'Amico AV; Haas-Kogan D; Alexander BM; Rahman R
JAMA Netw Open; 2021 Mar; 4(3):e213304. PubMed ID: 33779742
[TBL] [Abstract][Full Text] [Related]
23. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
24. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
25. Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer.
Samuel E; Zaman S; Bakar MA; Fareed MM
Discov Oncol; 2024 Feb; 15(1):27. PubMed ID: 38305836
[TBL] [Abstract][Full Text] [Related]
26. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
Royce TJ; Mavroidis P; Wang K; Falchook AD; Sheets NC; Fuller DB; Collins SP; El Naqa I; Song DY; Ding GX; Nahum AE; Jackson A; Grimm J; Yorke E; Chen RC
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):227-236. PubMed ID: 32900561
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
Lee SH; Kim HJ; Kim WC
Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.
Kishan AU; Karnes RJ; Romero T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Braccioforte M; Huland H; Tran PT; Martin S; Martínez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Chang AJ; Pisansky TM; Choo R; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; D'Amico AV; Rettig MB; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D
JAMA Netw Open; 2021 Jul; 4(7):e2115312. PubMed ID: 34196715
[TBL] [Abstract][Full Text] [Related]
29. Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.
Jiang P; Krockenberger K; Vonthein R; Tereszczuk J; Schreiber A; Liebau S; Huttenlocher S; Imhoff D; Balermpas P; Keller C; Dellas K; Baumann R; Rödel C; Hildebrandt G; Jünemann KP; Merseburger AS; Katz A; Ziegler A; Blanck O; Dunst J
Radiat Oncol; 2017 Aug; 12(1):138. PubMed ID: 28821268
[TBL] [Abstract][Full Text] [Related]
30. Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998-2016.
Beckmann K; Garmo H; Nilsson P; Franck Lissbrant I; Widmark A; Stattin P
Acta Oncol; 2020 May; 59(5):549-557. PubMed ID: 32122185
[No Abstract] [Full Text] [Related]
31. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
[TBL] [Abstract][Full Text] [Related]
32. Erectile function after stereotactic body radiotherapy for localized prostate cancer.
Dess RT; Hartman HE; Aghdam N; Jackson WC; Soni PD; Abugharib AE; Suy S; Desai NB; Zumsteg ZS; Mehra R; Morgan TM; Feng FY; Hamstra DA; Schipper MJ; Collins SP; Spratt DE
BJU Int; 2018 Jan; 121(1):61-68. PubMed ID: 28710895
[TBL] [Abstract][Full Text] [Related]
33. Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer.
Andruska N; Fischer-Valuck BW; Agabalogun T; Carmona R; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Baumann BC
Clin Genitourin Cancer; 2022 Apr; 20(2):123-131. PubMed ID: 35086762
[TBL] [Abstract][Full Text] [Related]
34. Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.
Moon DH; Basak RS; Usinger DS; Dickerson GA; Morris DE; Perman M; Lim M; Wibbelsman T; Chang J; Crawford Z; Broughman JR; Godley PA; Chen RC
Eur Urol; 2019 Sep; 76(3):391-397. PubMed ID: 30857758
[TBL] [Abstract][Full Text] [Related]
35. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic Body Radiation Therapy: A Radiosurgery Society Guide to the Treatment of Localized Prostate Cancer Illustrated by Challenging Cases.
Ma TM; Ladbury C; Tran M; Keiper TD; Andraos T; Gogineni E; Mohideen N; Siva S; Loblaw A; Tree AC; Cheung P; Kresl J; Collins S; Cao M; Kishan AU
Pract Radiat Oncol; 2024; 14(2):e117-e131. PubMed ID: 37661040
[TBL] [Abstract][Full Text] [Related]
37. Travel distance and stereotactic body radiotherapy for localized prostate cancer.
Mahal BA; Chen YW; Sethi RV; Padilla OA; Yang DD; Chavez J; Muralidhar V; Hu JC; Feng FY; Hoffman KE; Martin NE; Spratt DE; Yu JB; Orio PF; Nguyen PL
Cancer; 2018 Mar; 124(6):1141-1149. PubMed ID: 29231964
[TBL] [Abstract][Full Text] [Related]
38. Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer.
Wolf F; Sedlmayer F; Aebersold D; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Ghadjar P; Höcht S; Hölscher T; Müller AC; Niehoff P; Pinkawa M; Schmidt-Hegemann NS; Zamboglou C; Zips D; Wiegel T
Strahlenther Onkol; 2021 Feb; 197(2):89-96. PubMed ID: 33301049
[TBL] [Abstract][Full Text] [Related]
39. The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States.
Moore A; Stav I; Den RB; Gordon N; Sarfaty M; Neiman V; Rosenbaum E; Goldstein DA
J Oncol; 2019; 2019():8170428. PubMed ID: 30719039
[TBL] [Abstract][Full Text] [Related]
40. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
